Skip to main content
Study tests plitidepsin combo in patients with multiple myeloma

PharmaMar's Aplidin, or plitidepsin, taken in combination with dexamethasone was found by investigators to extend survival and time to disease progression or death in patients with relapsed or refractory multiple myeloma who have been heavily treated, compared with outcomes for those taking dexamethasone alone. Findings from the late-stage trial were published in the journal Annals of Hematology.

Full Story: